1. **S vs P is now identifiable enough to run.** The fatal prompt-length confound is fixed for the primary comparison. The remaining issue is comparator weakness, not non-identifiability.

2. **The placebo is imperfect but does not break the trial.** “Software engineering” is not fully orthogonal to building HTML pages: testing, dependency hygiene, error handling, and documentation can affect page quality. That likely biases **against S** on implementation quality, but the absence of design advice still makes S’s bar easier than a real design placebo. The author’s “weaker than generic design advice” framing is correct; calling it purely orthogonal is too strong.

3. **Drop the M2 switching rule.** Even if pre-registered, changing the confirmatory family based on observed tie rate is an outcome-dependent analysis path. Report M2 as degenerate/descriptive if ties are high, but do not let that change M1’s alpha.

4. Nothing makes a null impossible or a positive guaranteed. The main pro-positive pressure left is the weak placebo plus source-level M1 possibly rewarding treatment-induced implementation verbosity.

5. **NO-GO.** Single change to make it GO: remove the rule that drops M2 from the confirmatory family and keep the Holm family fixed as `{M1, M2}` regardless of M2 tie rate.
